Urovant Sciences to Present at the Jefferies Virtual London Healthcare Conference
10 Noviembre 2020 - 7:00AM
Business Wire
Urovant Sciences (Nasdaq: UROV) announced today that president
and chief executive officer James Robinson will give a presentation
at 6:10 p.m. GMT (10:10 a.m. PST / 1:10 p.m. EST) on Tuesday,
November 17, 2020, at the Jefferies Virtual London Healthcare
Conference.
A live, audio webcast for this event will be available on the
Investor Relations section of the Company’s website at
http://ir.urovant.com. A replay of the webcast will be available
for approximately 7 days.
About Urovant Sciences
Urovant Sciences is a clinical-stage biopharmaceutical company
focused on developing and commercializing innovative therapies for
urologic conditions. The Company’s lead product candidate,
vibegron, is an oral, once-daily small molecule beta-3 agonist that
is being evaluated for overactive bladder (OAB). Urovant Sciences
reported positive data from the vibegron 12-week, phase 3 pivotal
EMPOWUR study and demonstrated favorable longer-term efficacy,
safety, and tolerability in a 40-week extension study. The Company
submitted a New Drug Application to the FDA seeking approval of
vibegron for the treatment of patients with OAB in December 2019.
Vibegron is also being evaluated for treatment of OAB in men with
benign prostatic hyperplasia (OAB+BPH) and for abdominal pain
associated with irritable bowel syndrome (IBS). Urovant’s second
product candidate, URO-902, is a novel gene therapy being developed
for patients with OAB who have failed oral pharmacologic therapy.
Urovant Sciences, a subsidiary of Sumitomo Dainippon Pharma Co.,
Ltd., intends to develop novel treatments for additional urologic
diseases. Learn more about us at www.urovant.com.
About Sumitovant Biopharma Ltd.
Sumitovant is a global
biopharmaceutical company with offices in New York City and London.
Sumitovant is a wholly owned subsidiary of Sumitomo Dainippon
Pharma. Sumitovant is the majority shareholder of Urovant and
Myovant, and wholly owns Enzyvant, Spirovant, and Altavant.
Sumitovant's promising pipeline is comprised of early-through
late-stage investigational medicines across a range of disease
areas targeting high unmet need. For further information about
Sumitovant, please visit
https://www.sumitovant.com.
About Sumitomo Dainippon Pharma Co., Ltd.
Sumitomo Dainippon Pharma is among the top-ten listed
pharmaceutical companies in Japan, operating globally in major
pharmaceutical markets, including Japan, the U.S., China, and the
European Union. Sumitomo Dainippon Pharma is based on the 2005
merger between Dainippon Pharmaceutical Co., Ltd., and Sumitomo
Pharmaceuticals Co., Ltd. Today, Sumitomo Dainippon Pharma has more
than 6,000 employees worldwide. Additional information about
Sumitomo Dainippon Pharma is available through its corporate
website at https://www.ds-pharma.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201110005262/en/
Investor and Media Inquiries: Ryan Kubota 949.769.2706
ryan.kubota@urovant.com
Urovant Sciences (NASDAQ:UROV)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Urovant Sciences (NASDAQ:UROV)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024